Russell Investments Group
ARCT icon

Russell Investments Group’s Arcturus Therapeutics ARCT Stock Holding History

Russell Investments Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$510K Buy
75,903
+44,199
+139% +$348K ﹤0.01% 2774
2026
Q1 		$245K Sell
31,704
-12,721
-29% -$92.8K ﹤0.01% 2785
2025
Q4 		$272K Buy
44,425
+22,781
+105% +$246K ﹤0.01% 2723
2025
Q3 		$399K Sell
21,644
-1,674
-7% -$26.9K ﹤0.01% 2569
2025
Q2 		$303K Buy
23,318
+11,490
+97% +$136K ﹤0.01% 2520
2025
Q1 		$125K Buy
11,828
+11,799
+40,686% +$187K ﹤0.01% 2706
2024
Q4 		$492 Sell
29
-2,829
-99% -$53.3K ﹤0.01% 3612
2024
Q3 		$66.3K Buy
2,858
+792
+38% +$16.9K ﹤0.01% 2735
2024
Q2 		$50.3K Buy
2,066
+872
+73% +$26.4K ﹤0.01% 2762
2024
Q1 		$40.3K Buy
+1,194
New +$42.3K ﹤0.01% 2696
2023
Q4 		– Sell
-24
Closed -$613 – 3209
2023
Q3 		$613 Buy
+24
New +$739 ﹤0.01% 3385
2023
Q2 		– Sell
-4,300
Closed -$103K – 3449
2023
Q1 		$103K Buy
+4,300
New +$77.1K ﹤0.01% 2585

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Russell Investments Group's ARCT Position: Q2 2026 in Review

Russell Investments Group increased its Arcturus Therapeutics (ARCT) stake by 139% in Q2 2026, buying an estimated $348K and bringing the position to 75,903 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #2774.

Russell Investments Group first reported a position in ARCT in Q1 2023 and has held it in 12 quarters since. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Russell Investments Group held 75,903 shares of Arcturus Therapeutics worth $510K as of Q2 2026.
  • Russell Investments Group bought 44,199 Arcturus Therapeutics shares in Q2 2026, an estimated $348K.
  • Arcturus Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2774 holding.
  • Russell Investments Group first reported a position in Arcturus Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.